1
H-index
7
Jumlah Petikan /
Total Citation

dr. nur fa`izah binti ab muin

pensyarah perubatan

jabatan radiologi

 drfaizah_abmuin@ukm.edu.my



   Biografi/ Biography :






    •     Data Bibliometrik / Bibliometric Data
    Nota : Jumlah penerbitan adalah berdasarkan dari tahun pertama berkhidmat di UKM.
    Note : The number of publication is based from the first year working in UKM.
       Penerbitan Terkini / Latest Publication

    nur faizah ab muin, marniza saad, adlinda alip, muthukkumaran thiagarajan.  (2024).  the outcomes of glioblastoma multiforme: the university malaya medical centre experience 2008-2018.  - journal of health and translational medicine.  49-56. 

     

    nur fa'izah a, fuad i.  (2024).  primary mucinous carcinoma of the axillary skin: a case report & the role of adjuvant tamoxifen.  - medicine & health.  330-335. 

     

    nur faizah ab muin; marniza saad; adlinda alip; muthukkumaran thiagarajan.  (2023).  the outcomes of glioblastoma multiforme:the university malaya medical centre experience 2008-2018.  - annals of oncology.  S1411. 

     

    nor aniza azmi , caryn chan mei hsien , nur fa'izah ab muin , mimi syaqirah , ahmad syahmiuddin shamsuddin , afiqah shukri.  (2023).  development of psychosocial and supportive cancer patient care module for therapy radiographer in malaysia: student version.  - journal of medical imaging and radiationsciences.  S15. 

     

    nor aniza azmi , caryn chan mei hsien , nur fa'izah ab muin , ahmad syahmiuddin shamsuddin , mohd sukri nur afiqah , ab razak mimi syaqirah.  (2023).  development of a psychosocial and supportive cancer care module for therapy radiographers in malaysia: a systematic approach.  - journal of medical imaging and radiation sciences.  S15. 

     
    Lihat Seterusnya/More
       Penerbitan Berimpak Tinggi / High Impact Publication

    nur faizah ab muin; marniza saad; adlinda alip; muthukkumaran thiagarajan.  (2023).  the outcomes of glioblastoma multiforme:the university malaya medical centre experience 2008-2018.  - annals of oncology.  S1411. 

     

    izzati yussof, nur faizah ab muin, masnizah mohd, ernieda hatah, nor asyikin mohd tahir, noraida mohamed shah.  (2023).  breast cancer prevention and treatment misinformation on twitter: an analysis of two languages.  - digital health.  1-11. 

     
       Penerbitan SCOPUS/ERA / SCOPUS/ERA Publication

    nur faizah ab muin, marniza saad, adlinda alip, muthukkumaran thiagarajan.  (2024).  the outcomes of glioblastoma multiforme: the university malaya medical centre experience 2008-2018.  - journal of health and translational medicine.  49-56. 

     

    nur faizah ab muin; marniza saad; adlinda alip; muthukkumaran thiagarajan.  (2023).  the outcomes of glioblastoma multiforme:the university malaya medical centre experience 2008-2018.  - annals of oncology.  S1411. 

     

    izzati yussof, nur faizah ab muin, masnizah mohd, ernieda hatah, nor asyikin mohd tahir, noraida mohamed shah.  (2023).  breast cancer prevention and treatment misinformation on twitter: an analysis of two languages.  - digital health.  1-11. 

     

    nor aniza azmi , caryn chan mei hsien , nur fa'izah ab muin , ahmad syahmiuddin shamsuddin , mohd sukri nur afiqah , ab razak mimi syaqirah.  (2023).  development of a psychosocial and supportive cancer care module for therapy radiographers in malaysia: a systematic approach.  - journal of medical imaging and radiation sciences.  S15. 

     

    noraida mohamed shah, izzati yussof, nur faizah ab muin, norlia abdullah, ernieda hatah, nor asyikin mohd tahir.  (2023).  development and validation of a patient information booklet on endocrine therapy for breast cancer patients.  - malaysian journal of medicine and health sciences.  13. 

     
    Lihat Seterusnya/More
       Penerbitan Lain-lain / Other Publication

    nur faizah ab muin, ho gwo fuang.  (2019).  the response to anaplastic lymphoma kinase (alk) inhibitor in metastatic anaplastic thyroid carcinoma (atc).  - esmo asia congress 2019.  1. 

     
       Geran Kolaborasi Terkini / Latest Collaboration Grant
    Geran / Grant Kolaborator / Collaborator Status
    A PHASE 3 STUDY TO EVALUATE ZIMBERELIMAB (AB122) MONOTHERAPY COMPARED TO STANDARD CHEMOTHERAPY OR ZIMBERELIMAB COMBINED WITH AB154 IN FRONT-LINE, PD-L1-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER arcus biosciences inc
    83.3% (2021-03-25 sehingga 2025-12-24)
    A RANDOMIZED, DOUBLE-BLIND STUDY EVALUATING PHARMACOKINETIC SIMILARITY OF ABP 206 COMPARED WITH OPDIVO® (NIVOLUMAB) IN RESECTED STAGE III OR STAGE IV MELANOMA SUBJECTS IN THE ADJUVANT SETTING parexel international (malaysia) sdn bhd
    79.3% (2023-06-22 sehingga 2025-08-21)
    PHASE 1 STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF THE ANTI‑OX40 AGONIST MONOCLONAL ANTIBODY BGB-A445 IN COMBINATION WITH THE ANTI-PD-1 MONOCLONAL ANTIBODY TISLELIZUMAB IN PATIENTS WITH ADVANCED S beigene singapore pte. ltd
    77.7% (2022-11-10 sehingga 2025-11-09)
    A RANDOMIZED, OPEN-LABEL PHASE 2/3 STUDY OF BT8009 AS MONOTHERAPY OR IN COMBINATION IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CANCER (DURAVELO-2) bicycletx limited
    9.4% (2024-07-25 sehingga 2031-03-24)
    A GLOBAL, PHASE 3, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINETREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCE arrivent biopharma, inc
    27.8% (2023-07-27 sehingga 2029-05-26)
    Lihat Seterusnya/More
    A RANDOMIZED, DOUBLE-BLIND STUDY EVALUATING THE EFFICACY, SAFETY, AND IMMUNOGENICITY OF ABP 206 COMPARED WITH OPDIVO® (NIVOLUMAB) IN SUBJECTS WITH TREATMENT-NAïVE UNRESECTABLE OR METASTATIC MELANOMA parexel international (malaysia) sdn bhd
    27.8%(2024-01-04 sehingga 2025-10-03)
    A PHASE III, OPEN-LABEL, SPONSOR-BLIND, RANDOMIZED STUDY OF DATO-DXD WITH OR WITHOUT OSIMERTINIB VERSUS PLATINUM-BASED DOUBLET CHEMOTHERAPY FOR PARTICIPANTS WITH EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS... astrazeneca ab
    27.8%(2024-09-26 sehingga 2028-03-25)
    A PHASE III, OPEN-LABEL, SPONSOR-BLIND, RANDOMIZED STUDY OF DATO-DXD WITH OR WITHOUT OSIMERTINIB VERSUS PLATINUM-BASED DOUBLET CHEMOTHERAPY FOR PARTICIPANTS WITH EGFR-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS... parexel international (malaysia) sdn bhd.
    27.8%(2024-09-26 sehingga 2028-03-25)
    THE CORRELATION OF PD-L1 POSITIVITY WITH DNA MISMATCH REPAIR AND THEIR ASSOCIATIONS WITH TUMOUR-INFILTRATING LYMPHOCYTES IN TRIPLE NEGATIVE BREAST CANCER PATIENTS biomarketing services (m) sdn. bhd.
    27.8%(2024-11-01 sehingga 2026-10-31)
    THE CORRELATION OF PD-L1 POSITIVITY WITH DNA MISMATCH REPAIR AND THEIR ASSOCIATIONS WITH TUMOUR-INFILTRATING LYMPHOCYTES IN TRIPLE NEGATIVE BREAST CANCER PATIENTS jabatan patologi, hospital putrajaya
    27.8%(2024-11-01 sehingga 2026-10-31)
    ELACESTRANT VERSUS STANDARD ENDOCRINE THERAPY INWOMEN AND MEN WITH NODE-POSITIVE, ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, EARLY BREAST CANCER WITHHIGH RISK OF RECURRENCE—A GLOBAL, MULTICENTER, RANDOMIZED, OPEN-LABEL PHASE 3 STUDY (ELEGANT) stemline therapeutics, inc.
    27.8%(2025-01-09 sehingga 2033-01-08)
       Projek Penyelidikan / Research Projects
    Projek / Project Tempoh / Period Peranan / Role
    elacestrant versus standard endocrine therapy inwomen and men with node-positive, estrogen receptor-positive, her2-negative, early breast cancer withhigh risk of recurrence—a global, multicenter, randomized, open-label phase 3 study (elegant) 09-01-202508-01-2033 Ketua Projek
    a randomized, open-label phase 2/3 study of bt8009 as monotherapy or in combination in participants with locally advanced or metastatic urothelial cancer (duravelo-2) 25-07-202424-03-2031 Ketua Projek
    exploring nuclear security culture: a questionnaire-based survey 16-05-202415-11-2025 Ketua Projek
    an open-label, multi-center, single arm, rollover study of gme751 (proposed pembrolizumab biosimilar) in participants who are eligible for continued pembrolizumab treatment after participation in cgme751a12101 or cgme751a12301 studies 20-11-202419-05-2028 Penyelidik Bersama
    the correlation of pd-l1 positivity with dna mismatch repair and their associations with tumour-infiltrating lymphocytes in triple negative breast cancer patients 01-11-202431-10-2026 Penyelidik Bersama
    Lihat Seterusnya/More
       Bidang Kepakaran / Area of Expertise
    Nota : Maksimum 5 Bidang Kepakaran yang terkini dipaparkan./ Note : Maximum of 5 latest Area of Expertise is viewed.
       Pelajar Seliaan / Supervised Student
    3

    Sarjana /
    Master
    1

    Doktor Falsafah /
    Philosophy Doctor